These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12370520)

  • 1. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
    AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    Clark SA; Shulman NS; Bosch RJ; Mellors JW
    AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
    Haubrich RH; Jiang H; Swanstrom R; Bates M; Katzenstein D; Petch L; Fletcher CV; Fiscus SA; Gulick RM;
    HIV Clin Trials; 2007; 8(2):63-7. PubMed ID: 17507321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.